Bender Robert & Associates Gilead Sciences, Inc. Transaction History

Bender Robert & Associates

  • $455 Million
  • Q2 2024

A detailed history of Bender Robert & Associates transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bender Robert & Associates holds 18,713 shares of GILD stock, worth $1.58 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares
18,713
Previous 21,502 12.97%
Holding current value
$1.58 Million
Previous $1.58 Million 18.54%
% of portfolio
0.28%
Previous 0.37%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024
SELL
$71.58 - $87.29 $241,510 - $294,516
-3,374 Reduced 13.56%
21,502 $1.58 Million
Q4 2023

Jan 31, 2024
SELL
$73.27 - $83.09 $385,546 - $437,219
-5,262 Reduced 17.46%
24,876 $2.02 Million
Q3 2023

Oct 13, 2023
SELL
$73.94 - $80.67 $65,806 - $71,796
-890 Reduced 2.87%
30,138 $2.26 Million
Q2 2023

Jul 13, 2023
SELL
$76.01 - $86.7 $229,246 - $261,487
-3,016 Reduced 8.86%
31,028 $2.39 Million
Q1 2023

Apr 20, 2023
SELL
$77.31 - $88.08 $28,991 - $33,030
-375 Reduced 1.09%
34,044 $2.82 Million
Q4 2022

Feb 02, 2023
SELL
$62.32 - $89.47 $120,090 - $172,408
-1,927 Reduced 5.3%
34,419 $2.95 Million
Q3 2022

Oct 26, 2022
SELL
$59.54 - $68.01 $74,663 - $85,284
-1,254 Reduced 3.34%
36,346 $2.24 Million
Q2 2022

Jul 19, 2022
SELL
$57.72 - $65.01 $121,616 - $136,976
-2,107 Reduced 5.31%
37,600 $2.32 Million
Q1 2022

Apr 14, 2022
SELL
$57.92 - $72.58 $426,522 - $534,479
-7,364 Reduced 15.64%
39,707 $2.36 Million
Q3 2021

Nov 09, 2021
BUY
$67.69 - $73.03 $870,967 - $939,677
12,867 Added 37.62%
47,071 $3.29 Million
Q3 2021

Nov 03, 2021
SELL
$67.69 - $73.03 $1.05 Million - $1.13 Million
-15,484 Reduced 31.16%
34,204 $6.05 Million
Q2 2021

Jul 16, 2021
SELL
$63.47 - $69.35 $77,433 - $84,607
-1,220 Reduced 2.4%
49,688 $3.42 Million
Q1 2021

Apr 28, 2021
SELL
$60.0 - $68.46 $5,340 - $6,092
-89 Reduced 0.17%
50,908 $3.29 Million
Q4 2020

Jan 29, 2021
SELL
$56.65 - $64.55 $125,309 - $142,784
-2,212 Reduced 4.16%
50,997 $2.97 Million
Q3 2020

Oct 29, 2020
SELL
$62.1 - $78.08 $110,165 - $138,513
-1,774 Reduced 3.23%
53,209 $3.36 Million
Q2 2020

Jul 31, 2020
SELL
$72.34 - $84.0 $140,411 - $163,044
-1,941 Reduced 3.41%
54,983 $4.23 Million
Q1 2020

Apr 21, 2020
SELL
$62.63 - $80.22 $209,372 - $268,175
-3,343 Reduced 5.55%
56,924 $4.26 Million
Q4 2019

Jan 31, 2020
SELL
$61.62 - $67.78 $243,583 - $267,934
-3,953 Reduced 6.16%
60,267 $3.92 Million
Q3 2019

Oct 15, 2019
SELL
$62.51 - $69.0 $96,015 - $105,984
-1,536 Reduced 2.34%
64,220 $4.07 Million
Q2 2019

Jul 30, 2019
SELL
$61.87 - $69.38 $667,948 - $749,026
-10,796 Reduced 14.1%
65,756 $4.4 Million
Q1 2019

Apr 30, 2019
SELL
$62.53 - $70.05 $853,659 - $956,322
-13,652 Reduced 15.13%
76,552 $4.98 Million
Q4 2018

Jan 24, 2019
SELL
$60.54 - $79.0 $56,060 - $73,154
-926 Reduced 1.02%
90,204 $5.64 Million
Q3 2018

Oct 17, 2018
SELL
$71.28 - $78.92 $15,325 - $16,967
-215 Reduced 0.24%
91,130 $7.04 Million
Q2 2018

Jul 27, 2018
SELL
$64.88 - $75.68 $146,693 - $171,112
-2,261 Reduced 2.42%
91,345 $6.47 Million
Q1 2018

Apr 27, 2018
SELL
$72.84 - $88.8 $162,287 - $197,846
-2,228 Reduced 2.32%
93,606 $7.06 Million
Q4 2017

Jan 19, 2018
SELL
$71.15 - $83.52 $14,799 - $17,372
-208 Reduced 0.22%
95,834 $6.87 Million
Q3 2017

Oct 23, 2017
BUY
$72.11 - $85.47 $6.93 Million - $8.21 Million
96,042
96,042 $7.78 Million

Others Institutions Holding GILD

# of Institutions
1,880
Shares Held
1.02B
Call Options Held
12M
Put Options Held
8.96M
View Full List

About GILEAD SCIENCES, INC.

GILD Quotes by TradingView
  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $106B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Bender Robert & Associates Portfolio

Follow Bender Robert & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bender Robert & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Bender Robert & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email